BAY 73-6691
id:
bay-73-6691-185-1906001
title:
BAY 73-6691
text:
BAY 73-6691 is a drug developed by Bayer for the treatment of Alzheimer's disease. It was the first compound developed that acts as a phosphodiesterase inhibitor selective for the PDE9A subtype. The PDE9A enzyme is expressed primarily in the brain, with high concentrations in the cerebellum, neocortex, striatum, and hippocampus, and acts to limit the cGMP-mediated signal transduction which occurs following glutamate binding to NMDA receptors. Consequently, selective PDE9A inhibitors were predict
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/BAY_73-6691
date created:
2008-12-09T23:20:41Z
date modified:
2024-09-07T19:55:42Z
main entity:
{"identifier":"Q4834702","url":"https://www.wikidata.org/entity/Q4834702"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/2/24/BAY_73-6691.svg","width":512,"height":365}
fields total:
13
integrity:
16